• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甘精胰岛素和利西那肽对 2 型糖尿病患者β细胞功能的影响:一项随机开放标签研究。

Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.

机构信息

Diabetes Division, Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Profil, Neuss, Germany.

出版信息

Diabetes Obes Metab. 2017 Nov;19(11):1625-1629. doi: 10.1111/dom.12968. Epub 2017 May 31.

DOI:10.1111/dom.12968
PMID:28407415
Abstract

It is known that β-cell function can be enhanced by direct stimulation of insulin secretion or by induction of β-cell rest, but whether both strategies can complement each other has not yet been examined. A total of 28 people with type 2 diabetes (glycated haemoglobin 7.8% ± 0.5%) were treated with either lixisenatide or titrated insulin glargine, followed by their combined administration, each over 4 weeks. First- and second-phase insulin secretion during an intravenous glucose challenge were calculated. First- and second-phase insulin secretion were not increased with glargine alone, but increased after addition of lixisenatide ( P  < .001). Lixisenatide alone increased first- and second-phase insulin secretion ( P  < .01). Addition of insulin glargine tended to further increase first-phase insulin secretion (P = .054), as well as insulin and C-peptide concentrations ( P  < .05). Second-phase insulin secretion was not affected by the addition of glargine. The sequence of initiating lixisenatide or glargine had no effect on the final measures of glycaemia or insulin secretion. Thus, lixisenatide and, to a lesser extent, insulin glargine, increase glucose-stimulated insulin secretion in an additive manner.

摘要

已知β细胞功能可以通过直接刺激胰岛素分泌或诱导β细胞休息来增强,但这两种策略是否可以互补尚未得到检验。共有 28 名 2 型糖尿病患者(糖化血红蛋白 7.8%±0.5%)接受了利西那肽或甘精胰岛素滴定治疗,随后联合治疗,每种治疗持续 4 周。计算了静脉葡萄糖负荷试验期间的第一和第二相胰岛素分泌。甘精胰岛素单独使用不会增加第一和第二相胰岛素分泌,但添加利西那肽后会增加(P<0.001)。利西那肽单独使用可增加第一和第二相胰岛素分泌(P<0.01)。添加甘精胰岛素可能会进一步增加第一相胰岛素分泌(P=0.054),以及胰岛素和 C 肽浓度(P<0.05)。添加甘精胰岛素不会影响第二相胰岛素分泌。起始利西那肽或甘精胰岛素的顺序对最终血糖和胰岛素分泌测量没有影响。因此,利西那肽和在较小程度上的甘精胰岛素以附加方式增加葡萄糖刺激的胰岛素分泌。

相似文献

1
Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.甘精胰岛素和利西那肽对 2 型糖尿病患者β细胞功能的影响:一项随机开放标签研究。
Diabetes Obes Metab. 2017 Nov;19(11):1625-1629. doi: 10.1111/dom.12968. Epub 2017 May 31.
2
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.在 LixiLan-O 试验中,评估了可滴定固定比例的胰岛素甘精/利西那肽(iGlarLixi)与胰岛素甘精和利西那肽单药治疗的疗效,基线糖化血红蛋白、糖尿病病程和体重指数对其临床结局的影响。
Diabetes Obes Metab. 2017 Dec;19(12):1798-1804. doi: 10.1111/dom.12980. Epub 2017 Jul 7.
3
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.利西那肽和利拉鲁肽对优化胰岛素甘精胰岛素联合或不联合二甲双胍治疗的 2 型糖尿病患者餐后血糖控制、胃排空和安全性参数的对比影响:一项随机、开放标签试验。
Diabetes Care. 2015 Jul;38(7):1263-73. doi: 10.2337/dc14-1984. Epub 2015 Apr 17.
4
Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.胰岛素甘精和利西那肽 1:1 固定比例复方制剂与利西那肽治疗口服降糖药控制不佳的日本 2 型糖尿病患者的疗效和安全性:LixiLan JP-O1 随机临床试验。
Diabetes Care. 2020 Jun;43(6):1249-1257. doi: 10.2337/dc19-2452. Epub 2020 Apr 15.
5
Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.精蛋白锌重组赖脯胰岛素混合注射液(25R)基础上固定比例联用利西拉来肽:简化 2 型糖尿病患者血糖控制方案。
Diabetes Res Clin Pract. 2020 Dec;170:108478. doi: 10.1016/j.diabres.2020.108478. Epub 2020 Sep 28.
6
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.餐时选择以推进基础胰岛素甘精胰岛素治疗:在 2 型糖尿病中测试利西那肽联合基础胰岛素与赖脯胰岛素,分别作为基础-餐时或基础-追加方案:GetGoal Duo-2 试验。
Diabetes Care. 2016 Aug;39(8):1318-28. doi: 10.2337/dc16-0014. Epub 2016 May 23.
7
The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.甘精胰岛素与格列美脲对二甲双胍单药治疗血糖控制不佳的2型糖尿病患者胰岛β细胞功能的影响:开放标签、随机对照研究
Acta Diabetol. 2014 Apr;51(2):277-85. doi: 10.1007/s00592-013-0553-z. Epub 2014 Jan 21.
8
Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).利西那肽对比西格列汀治疗基础胰岛素甘精胰岛素治疗的日本 2 型糖尿病患者餐后血糖的降低作用:一项随机、四期研究(NEXTAGE 研究)。
Diabetes Obes Metab. 2017 Sep;19(9):1252-1259. doi: 10.1111/dom.12945. Epub 2017 Apr 27.
9
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.根据既往胰岛素使用情况,甘精胰岛素100U/mL与利司那肽合剂(iGlarLixi)在2型糖尿病患者中的实际疗效。
Diabetes Obes Metab. 2024 Jul;26(7):2988-2992. doi: 10.1111/dom.15609. Epub 2024 Apr 29.
10
Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.在 GetGoal-O 研究中,利西那肽作为附加疗法用于 2 型糖尿病老年患者的基础胰岛素治疗的疗效和安全性。
J Diabetes. 2019 Dec;11(12):971-981. doi: 10.1111/1753-0407.12952. Epub 2019 Jun 26.

引用本文的文献

1
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.在一项随机临床试验中,针对早期 2 型糖尿病缓解目标,添加 exenatide 到基础胰岛素治疗的代谢效应。
Nat Commun. 2022 Oct 16;13(1):6109. doi: 10.1038/s41467-022-33867-9.
2
Impact of the Fasting Plasma Glucose Titration Target on the Success of Basal Insulin Titration in Insulin-Naïve Patients with Type 2 Diabetes: A Systematic Analysis.空腹血糖滴定目标对新诊断 2 型糖尿病患者基础胰岛素剂量调整成功率的影响:系统分析。
J Diabetes Res. 2022 Jul 30;2022:4758042. doi: 10.1155/2022/4758042. eCollection 2022.